A Phase 2 Study to Compare the Efficacy and Tolerability of Tarafenacin 0.2 mg and Tarafenacin 0.4 mg to Placebo in Patients Suffering From Overactive Bladder.

• Status: Completed
• Trial end date: 2012-11-01

Summary

1. Primary Objective:

To evaluate the dose-response relationship of tarafenacin on efficacy.

2. Secondary Objectives:

• To compare 12 weeks' efficacy of different doses of tarafenacin to that of placebo in patients suffering from Overactive Bladder. .

• To compare the tolerability of different doses of tarafenacin to that of placebo in patients suffering from Overactive Bladder. .

• Phase: Phase 2

Details

• Lead Sponsor: Kwang Dong Pharmaceutical co., ltd.